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Preamble
Thoracic endovascular aortic repair (TEVAR) is an emerging treatment
modality, which has been rapidly embraced by clinicians treating thor-
acic aortic disease.1–4 Fundamentally, it is a far less invasive approach
than open surgery and its availability and relative ease of application
has changed and extended management options in thoracic aortic
disease, including in those patients deemed unfit or unsuitable for
open surgery. In the operating room, this requires considerable per-
ceptual, cognitive and psychomotor demands on the operators.
The dramatic expansion of TEVAR activity has necessarily
prompted a requirement to systematically consider the indications,
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appropriateness, limitations and delivery of this treatment, which
has been adopted by many specialties including cardiologists, cardio-
vascular surgeons, radiologists and vascular surgeons.5 Our task has
been to generate a multidisciplinary position statement that sup-
ports and advises all clinicians utilizing this technological advance.
This document focuses on the main diagnoses—thoracic aortic an-
eurysm (TAA), thoracic aortic dissection (TAD) of the descending
aorta (type B according to the Stanford classification) and thoracic
aortic injury (TAI)—indications and applicability of TEVAR and
includes information regarding its limitations and complications. It
acts as a position statement for both societies that reflects
current understanding of thoracic aortic endovascular therapy.
Recommendations for the
Development of a TEVAR
Programme
Evaluation of symptoms and patient
status
Symptoms in patients with TAA and chronic dissection are rare
and non-specific.6,7 New onset of hoarseness or dysphagia may
suggest a developing aneurysm in the distal aortic arch and prox-
imal descending aorta. Most asymptomatic cases are discovered in-
cidentally, while symptomatic patients have usually developed
complications. Even in patients with acute aortic syndromes,
chest pain, back pain and signs of malperfusion are often misinter-
preted due to lack of awareness. In cases of clinical suspicion, a
computed tomography (CT)-angiography is the diagnostic
modality of first choice.
Multidisciplinary consultation
Patient selection should be performed on an individual basis
according to anatomy, pathology, comorbidity and anticipated dur-
ability of any repair, using a multidisciplinary approach, ideally in an
aortic centre. This concept offers the widest available opinion, an
appropriate range of technical options and adequate infrastructure
for endovascular therapy of thoracic aortic disease. The involve-
ment of different specialties allows combining the best experience
and expertise in medical, interventional and surgical therapy for
tailoring an optimal treatment strategy for the individual patient.
Preoperative imaging
CT angiography (CTA) is the method of choice for diagnosis and
planning treatment.8 Magnetic resonance imaging (MRI) is not
widely used in the acute setting, but may be useful in chronic
disease and during follow-up.9 Conventional angiography is no
longer recommended as a routine diagnostic procedure. Positron
emission tomography in combination with CTA may be used as
an adjunct in specific situations (detection of signs of inflammation)
but is not recommended for routine use.10,11
Intraprocedural imaging
High-quality imaging and appropriate facilities for open surgery
during the endovascular procedure are of the utmost importance.
Purpose-built, hybrid operating and imaging suites appear to be the
optimal solution.12 Transoesophageal echocardiography (TEE) is
recommended as an adjunctive intraoperative imaging technique
in complex aortic pathologies such as aortic dissection.13–15 Intra-
vascular ultrasound and phased-array intracardiac ultrasound could
be useful as well in cases of dissection.16,17
Postprocedural imaging
CTA prior to discharge is advised to delineate complications
undetected during the initial endovascular procedure and to
form a reference for follow-up studies. To avoid radiation MRI
may be more widely used in the future,8 but it lacks the visualiza-
tion of metallic stent struts and is not compatible with stainless
steel endografts.18
Risk evaluation
To date, no TEVAR-specific risk stratification tool is available.
Clearly, an individual risk stratification tool is required to
predict endovascular outcomes and it will be the task of such
working groups to establish a suitable tool in the near future.
Until such risk stratification tools are available, individual patient’s
decisions will be made on the traditional basis of risk–benefit
analysis.19
Adjunctive diagnostic modalities
It is recommended that a transthoracic echocardiogram be per-
formed as part of the diagnostic work-up in the elective setting
in order to exclude valvular and structural heart disease. Further
imaging should include a duplex ultrasound of the supraaortic
vessels. A stress test to exclude coronary artery disease is not
necessary in asymptomatic patients.20,21 Cardiac catheterization
is suggested in patients with proven signs and symptoms of
ischaemia or suspicion of coronary artery disease.
Planning of TEVAR—TAA
A sufficient proximal and distal landing zone of at least 2 cm is
necessary for the safe deployment and durable fixation of
TEVAR.22,23 If landing zones are shorter or significantly angu-
lated, prior transposition or bypass surgery/re-routing of the
involved aortic branch may be considered. Evaluation of access
vessels (sizing, calcification, tortuosity) is of major importance.
An access vessel of at least 8 mm in diameter is necessary for
a standard 24 French delivery device. Alternative access sites
are the iliac arteries, the infrarenal aorta or even the ascending
aorta.
Planning of TEVAR—type B TAD
Planning of TEVAR includes clinical examination, laboratory tests
and imaging to classify the type of dissection (classical dissection,
intramural haematoma (IMH), penetrating atherosclerotic ulcer,
traumatic dissection), its duration and potential complications.
Localization of all tears, with emphasis on identifying the primary
entry tear, is important. The next step is to define the extension
of dissection and possible static, dynamic or complex involvement
of supraaortic, visceral and pelvic vessels resulting in malperfusion.8
Perfusion of side branch vessels through the false lumen does
not automatically exclude patients from TEVAR, as a distal
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communication is often present or the visceral vessel may receive a
contribution from both lumina.
Indications and contraindications
for TEVAR
TEVAR for TAA
In asymptomatic TAA patients TEVAR is indicated (by consensus)
when the maximum diameter of the aneurysm exceeds 5.5 cm or if
rapid expansion (.5 mm in 6 months) occurs.24,25 In certain mor-
phologic situations which are considered prone to rupture, e.g.
saccular aneurysms, TEVAR may be justified at a diameter of less
the above referenced 5.5 cm. Comorbidities and age of the
patient have to be considered,26 and it may be appropriate to
set a larger aortic diameter threshold in patients with increased
operative risk.
TEVAR for type B aortic dissection
TEVAR is the treatment modality of choice in complicated acute
type B aortic dissections.3,27–29 The term ‘complicated’ means per-
sisting or recurrent pain, uncontrolled hypertension despite full
medication, early aortic expansion, malperfusion and signs of
rupture (haematothorax, increasing periaortic and mediastinal
haematoma).28 Further subgroups benefiting from immediate
TEVAR are being defined. In an uncomplicated type B dissection,
a primary conservative approach with close surveillance seems
to be justified until complications arise.30 The treatment of aneur-
ysms on the basis of chronic type B dissections should be discussed
in a multidisciplinary team approach, considering TEVAR versus
open surgery.31
In cases of penetrating aortic ulcer, treatment may be recom-
mended, when patients are symptomatic, or the ulcer demon-
strates expansion and IMH.32 In patients with IMH, intimal
lesions/laceration can often be found in the inner curvature of
the aortic arch by careful CTA analysis. This may be an aim for
stent-graft implantation in patients with a progressive/complicated
IMH.32
TEVAR for traumatic aortic injury
Immediate endovascular treatment is indicated in patients with
complete transsection of the aortic wall and free bleeding into
the mediastinum or pseudocoarctation syndrome, whereas
delayed treatment can be suggested when limited disruption of
the aorta is present but media and adventitia are intact.33–35
Connective tissue disease
TEVAR is not recommended in patients with connective tissue
disease except as a bail-out procedure or bridge to definitive
open surgical therapy, or as a procedure following prior aortic
repair when both landing zones lie within previously sited pros-
thetic grafts (e.g. intercostal patch aneurysm after Marfan’s TAA
repair).36,37
Endoleaks
Definition of endoleak after TEVAR
for TAA
Type I (proximal and/or distal reperfusion of the aneurysmal sac)
and type III endoleaks (endograft/endograft disconnection leaks)
are regarded as treatment failures and warrant further treatment
to prevent the continuing risk of rupture.38 Type II endoleaks
(retrograde perfusion via branch vessels) are managed primarily
conservatively by a ‘wait and watch’ strategy to detect aneurysmal
expansion, except for supraaortic arteries. In these patients coil
embolization, plug occlusion or surgical ligation should be per-
formed during or early after the TEVAR procedure. Type IV (endo-
graft porosity) and type V (endotension) endoleaks are historical
phenomena and are no longer observed with more recent
technology.39
Definition of endoleak after TEVAR
for TAD
The only important types of endoleaks in TAD are type Ia (ante-
grade perfusion of the false lumen) and type II (perfusion of the
false lumen via the overstented left subclavian artery). Retrograde
flow from distal entry tears must not be considered as endoleaks.
Definition of treatment success
TAA
Procedural ‘technical’ success is achieved when the endograft is
deployed accurately and the aneurysm is excluded from the circu-
lation (i.e. absence of type I or III endoleak). Evaluation of clinical
success requires follow-up examinations of the patient demon-
strating complete thrombosis and shrinkage of the aneurysm sac,
and in the absence of complications.
TAD
Procedural ‘technical’ success is defined as closure of the primary
entry tear (i.e. absence of type Ia endoleak) and induction of false
lumen thrombosis. The aim of endovascular treatment is to over-
come or resolve complications of aortic dissection including mal-
perfusion, imminent rupture and bleeding. This does not imply
complete immediate thrombosis of the false lumen, as further
thrombosis and remodelling processes are a matter of time.
Current techniques for TAAS
and TADS
Available endovascular systems
It is beyond the scope of this statement to address all manufac-
turers as well as their advantages and drawbacks. The aim of this
section is to briefly discuss the different concepts regarding
design and mode of deployment. Regarding design, devices with
or without proximal uncovered struts are available. The aim of
proximal uncovered struts is to enhance proximal fixation of the
prosthesis, and ensure adequate alignment of the endograft.
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However, adverse events potentially associated with bare stents in-
cluding retrograde type A dissection have been reported.40,41
Whether these observations are causal or not remains undefined.
In terms of deployment, there is a choice between devices with
and without a tip-capture system.42,43 It would appear that the
availability of a tip capture may increase safety, as blood pressure
or anatomy-dependent migration or displacement of the prosthesis
during deployment is reduced. A tip-capture system is recom-
mended in patients, where proximal stent-graft deployment is
needed (cranial ascending aorta, arch).
Specifics of TEVAR for TAA
Detailed attention has to be paid to the length of the landing zone,
sufficient overlapping if more than one prosthesis is being used, as
well as angulation in the aorta and iliac arteries. The stent-graft
diameter should exceed the diameter of the landing zones by at
least 10–15% of the reference aortic diameter. Anatomic con-
straints in the infrarenal aorta or the thoracoabdominal transition
with excessive tortuosity may lead to a loss of pushability and
may preclude advancement of the prosthesis into the area of inter-
est. These difficult situations may be overcome using, in addition to
a superstiff guidewire, a second protected stiff buddy wire or a
pull-through procedure via the brachial artery.
Specifics of TEVAR for TAD
The focus is the occlusion of the primary entry tear. The size of the
selected stent graft should be based on the diameter of the aorta
proximal to the dissected segment, applying almost no oversizing.
The technical challenge, especially in complicated type B dissec-
tions, may be to cannulate the narrowed, sometimes collapsed
true lumen. To assure access to the true lumen, TEE may often
be necessary.44 Procedure-related difficulties may be overcome
by an antegrade approach via the brachial artery with the guidewire
being snared in the aorta. After deployment, ballooning is not
recommended, even if the stent graft is not fully expanded,
because of the self-expanding nature of the stent and the time
required for the remodelling process of the aorta. Retrograde dis-
section and rupture of the dissection membrane has been
reported due to ballooning.
Intraprocedural monitoring
and blood pressure control
Invasive blood pressure monitoring is required on a routine basis.
Cardiovascular anaesthesiologists trained in endovascular proce-
dures are desirable. Pharmacological lowering of blood pressure
,80 mmHg systolic during stent-graft deployment may be suffi-
cient in many cases to avoid displacement of the device. If
further blood pressure lowering is required in proximal aortic pro-
cedures, then rapid pacing is the method of choice.45
Vascular access
Surgical cut-down is traditionally regarded as the safest way to fully
control access vessels. Percutaneous approaches are increasingly
used with a wide variety of techniques. At present, the diameter
and calcification of the vessel represent major limitations of
these devices.46 Further reduction in the profile of stent-graft
delivery device will expand the indication for percutaneous
approaches.
Combined procedures
Combined surgical and endovascular techniques—so-called hybrid
procedures—have become popularized during the last decade.
Staged conventional surgical repair is associated with significant
morbidity and mortality, due to the summation of possible compli-
cations between first operation, waiting period and second surgical
intervention.47
In principle, two different approaches to extensive disease of the
aortic arch and proximal descending aorta were developed: First,
the ‘frozen elephant trunk’ technique involves conventional surgi-
cal repair of the ascending aorta and the aortic arch combined
with open antegrade stent grafting of the descending aorta in the
period of circulatory arrest.48–50 Second, re-routing of supraaortic
branches by transposition or bypass enables endovascular treat-
ment of the arch and proximal descending aorta without
need for cardiopulmonary bypass and hypothermic circulatory
arrest.23,51 Visceral and renal transpositions cannot be recom-
mended as standard procedures for thoraco-abdominal aneurysms
as the early results of these procedures have revealed high mortal-
ity rates.52 Clearly, further larger series need to be awaited.
Techniques for non-surgical side
branch access
Aortic pathologies involving major side branches are a complex
challenge for endovascular repair. Implantation of a stent-graft
may result in critical ischaemia and organ dysfunction. Recently,
there has been increasing interest in the development of catheter-
based non-surgical techniques to address this issue. Approaches
include: (1) development of dedicated stent-graft prostheses with
fenestrations or branches for direct side branch access, and (2)
modification of readily available interventional techniques to estab-
lish extra-anatomic side branch perfusion (e.g. ‘Chimney’, ‘Sand-
wich’ technique etc.). All these techniques are still investigational
as sufficient follow-up is not yet available; such procedures are
not endorsed and should be limited to clinical trials in centres of
excellence or with a particular interest until broader knowledge
supports the technique.53
Procedure-related complications
Any vascular injury or vessel-associated injury (thrombosis, bleed-
ing, retrograde type A dissection, stroke) during TEVAR and within
24 h, as well as cardiac complications (perforation of a superstiff
guidewire, myocardial injury of any kind) should be reported as
procedure-related.54
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Stent graft related complications
The most significant complication is retrograde type A dissec-
tion.40,41 Associated factors may include radial force of uncovered
struts, diagnosis of TAD, extensive oversizing and ballooning.
Erosion of the oesophagus or the left main bronchus is an ex-
tremely rare complication and potentially more related to the
underlying disease than to the stent graft.55,56 Finally, in TAD,
membrane rupture at the distal end of the stent graft may occur.
This rare event is likely to be related rather to the underlying
disease, than to the size of the stent graft itself.
Outcome parameters
TEVAR for TAA
The main outcome parameters are survival and aortic-related sur-
vival.22,57 Other clinically significant outcome parameters would
include rate of persisting or newly developing endoleakage,
freedom from reintervention or secondary surgical conversion.
Summarizing the available literature, outcomes are encouraging,
but seem to be predominantly determined by age and
co-morbidities.22,26,58
TEVAR for TAD
Measures of outcome are identical to those of TAA. However,
additional information needs to encompass the fate of the distal
aorta involved in the dissection. The closure rate of the primary
entry tear and thrombosis of the false lumen of the stented
segment of the thoracic aorta is high in most series, but needs
to be reported in the long term.54 It seems reasonable to accept
continued perfusion of the false lumen in the abdomen distal
from the stent-graft site as long as aortic dilatation does not
occur.59,60
Evaluation of results
Follow-up after TEVAR
Lifelong clinical and morphological surveillance is mandatory after
TEVAR as late treatment failure may develop even years after
the initial treatment.61 Currently CTA is recommended prior to
discharge. Further follow-ups at 6 and 12 months is based on
CTA, thereafter MRI/CTA in addition to annual clinical follow-up
should be implemented. The imaging algorithm in case of detect-
able endoleaks cannot be generalized and remains according to
the individual discretion of the treating physician.
Pending questions
Malperfusion
TEVAR has proved to be the modality of choice in the treatment of
malperfusion from dynamic true lumen compression. Additional
branch vessel stenting may be necessary in order to resolve mal-
perfusion related to static obstruction (false lumen thrombosis).
Interventional or surgical fenestration of the dissecting membrane
is not considered as first line therapy.28 So far, the value of
extending the stented aortic segment into the abdominal aorta
for persisting malperfusion after TEVAR by implantation of add-
itional uncovered stents distally (PETTICOAT concept) requires
further data collection and evaluation.62
Endoleaks
The majority of endoleaks can be avoided by careful selection
particularly with regard to important morphological details such
as the length of the landing zone, use of multiple stents, length
of overlapping segments as well as severe angulation and massive
aortic calcification (porcelain aorta).61
TEVAR induced neurologic injury: brain
Brain injury after TEVAR is a major complication and most often
associated with the underlying pathology, excessive device manipu-
lation within the arch or intended or inadvertent overstenting of
one or more of the great vessels. Further reduction in the
stroke rate will be feasible by aggressively maintaining antegrade
cerebral perfusion through prior vascular transposition.23 Over-
stenting of the left subclavian artery is permissible in the emer-
gency setting (e.g. traumatic aortic injury), but is inadvisable in
elective cases due to a heightened risk of stroke and spinal cord
injury. Therefore, detailed information on cerebral blood supply
is required in elective situations.63,64
TEVAR induced neurologic injury: spinal
cord
Spinal cord injury can occur immediately after TEVAR or be
delayed, requiring clinical and neurological surveillance. The risk
may be increased with extended lengths of the covered thoracic
aortic segments.65 Recent reports underline the importance of
maintaining collateral blood supply via the left subclavian artery,
lumbar arteries as well as hypogastric arteries. Special attention
has to be paid to patients with previous treatment of AAA and
intended coverage of subclavian artery by TEVAR. In such cases
pre-deployment subclavian transposition would appear mandatory.
In high-risk patients, preventive cerebrospinal fluid (CSF) drainage,
which has proven efficacy in spinal cord protection during open
thoraco-abdominal aneurysm surgery, is strongly recommended.66
Reversal of paraplegia can be achieved by the immediate initi-
ation of CSF drainage and pharmacological elevation of blood pres-
sure (.90 mmHg mean arterial pressure). Hypotensive episodes
during the procedure should be avoided. Neurological outcomes
seem to be better with delayed occurrence of paraplegia than
with immediate paraplegia after TEVAR.67 Finally, a highly normal
serum haemoglobin as well as precise attent to oxygenation will
serve to both, prevention and reversal.
Vascular complications
Vascular complications are rare when anatomy is respected.
Furthermore, the introduction of hydrophilic delivery sheaths has
substantially facilitated the introduction of devices in relatively
small access vessels. In calcified vessels, open surgical cut-down
is preferred.46
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Retrograde aortic dissection
Retrograde aortic dissection may occur after TEVAR. However, it
is seen more frequently in acute aortic dissection and procedures
where the aortic arch or the ascending aorta is involved. The role
of bare proximal stents in retrograde type A dissection remains
undefined.40,41
Aorto-oesophageal or aorto-bronchial
fistulation
Fistulation after TEVAR is rare and more frequently seen after
acute aortic syndromes than after elective procedures. The final
common pathway in development may be local inflammation in
the posterior mediastinum.55,56 The treatment of choice is
radical oesophageal resection comparable to treatment of
oesophageal cancer.
Perspectives
Progress of device development
Challenges in endograft design are the development of branched
endografts and of pathology-specific endografts.68–70 However,
the unique composition of the proximal thoracic aorta as well as
the associated mechanical properties have to be taken into
account and make this effort by far more complex than initially
expected. There is a need for reducing the dimension (outer diam-
eter) of the stent-graft devices, increasing the conformability and
trackability.
Pressure sensors
Despite the convincing concept, there are no data showing that
pressure sensors are superior to conventional imaging in order
to detect or prevent aortic-related adverse events.71 Development
of so-called ‘smart’ stents has to be expected.
Progress of imaging
Recently, there has been increasing interest in functional imaging
(assessment of flow patterns, membrane dynamics, diameters
during the cardiac cycle, wall stress), which will help to improve
our understanding of aortic diseases and may be able to predict
future events.72 This may be complemented by molecular
imaging of the aortic wall metabolism, which will provide important
insights into the pathogenesis and healing process.10
Synopsis and outlook
TEVAR has changed aortic medicine, enhancing the armamentar-
ium of the aortic specialist in treating acute and chronic thoracic
aortic disease. TEVAR offers a valid treatment option for the
elderly patients deemed at excessive risk for open surgery, but
also for fit patients with suitable anatomies. Particularly, in patients
with traumatic aortic injury and acute complicated TAD, TEVAR is
considered the treatment of choice. A prerequisite is a multidiscip-
linary team approach in centres with a dedicated interest in aortic
diseases. Therefore, the foundation of specialized aortic centres
providing the full range of diagnostic and treatment options is
strongly recommended.
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